Literature DB >> 25779992

Independent dose calculations for commissioning, quality assurance and dose reconstruction of PBS proton therapy.

G Meier1, R Besson, A Nanz, S Safai, A J Lomax.   

Abstract

Pencil beam scanning proton therapy allows the delivery of highly conformal dose distributions by delivering several thousand pencil beams. These beams have to be individually optimised and accurately delivered requiring a significant quality assurance workload. In this work we describe a toolkit for independent dose calculations developed at Paul Scherrer Institut which allows for dose reconstructions at several points in the treatment workflow. Quality assurance based on reconstructed dose distributions was shown to be favourable to pencil beam by pencil beam comparisons for the detection of delivery uncertainties and estimation of their effects. Furthermore the dose reconstructions were shown to have a sensitivity of the order of or higher than the measurements currently employed in the clinical verification procedures. The design of the independent dose calculation tool allows for a high modifiability of the dose calculation parameters (e.g. depth dose profiles, angular spatial distributions) allowing for a safe environment outside of the clinical treatment planning system for investigating the effect of such parameters on the resulting dose distributions and thus distinguishing between different contributions to measured dose deviations. The presented system could potentially reduce the amount of patient-specific quality assurance measurements which currently constitute a bottleneck in the clinical workflow.

Entities:  

Mesh:

Year:  2015        PMID: 25779992     DOI: 10.1088/0031-9155/60/7/2819

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  8 in total

Review 1.  Online daily adaptive proton therapy.

Authors:  Francesca Albertini; Michael Matter; Lena Nenoff; Ye Zhang; Antony Lomax
Journal:  Br J Radiol       Date:  2019-11-11       Impact factor: 3.039

2.  Fraction-variant beam orientation optimization for intensity-modulated proton therapy.

Authors:  Wenbo Gu; Daniel O'Connor; Dan Ruan; Wei Zou; Lei Dong; Ke Sheng
Journal:  Med Phys       Date:  2020-08-02       Impact factor: 4.071

Review 3.  Adaptive proton therapy.

Authors:  Harald Paganetti; Pablo Botas; Gregory C Sharp; Brian Winey
Journal:  Phys Med Biol       Date:  2021-11-15       Impact factor: 3.609

4.  Clinical Implementation of a Proton Dose Verification System Utilizing a GPU Accelerated Monte Carlo Engine.

Authors:  Chris Beltran; H Wan Chan Tseung; Kurt E Augustine; Martin Bues; Daniel W Mundy; Timothy J Walsh; Michael G Herman; Nadia N Laack
Journal:  Int J Part Ther       Date:  2016-12-30

5.  Validation of dose distribution for liver tumors treated with real-time-image gated spot-scanning proton therapy by log data based dose reconstruction.

Authors:  Takahiro Yamada; Seishin Takao; Hidenori Koyano; Hideaki Nihongi; Yusuke Fujii; Shusuke Hirayama; Naoki Miyamoto; Taeko Matsuura; Kikuo Umegaki; Norio Katoh; Isao Yokota; Hiroki Shirato; Shinichi Shimizu
Journal:  J Radiat Res       Date:  2021-07-10       Impact factor: 2.724

6.  Automated Monte-Carlo re-calculation of proton therapy plans using Geant4/Gate: implementation and comparison to plan-specific quality assurance measurements.

Authors:  Adam H Aitkenhead; Peter Sitch; Jenny C Richardson; Carla Winterhalter; Imran Patel; Ranald I Mackay
Journal:  Br J Radiol       Date:  2020-07-29       Impact factor: 3.039

7.  Online adaptive dose restoration in intensity modulated proton therapy of lung cancer to account for inter-fractional density changes.

Authors:  Elena Borderías Villarroel; Xavier Geets; Edmond Sterpin
Journal:  Phys Imaging Radiat Oncol       Date:  2020-07-13

Review 8.  Personalised computational cardiology: Patient-specific modelling in cardiac mechanics and biomaterial injection therapies for myocardial infarction.

Authors:  Kevin L Sack; Neil H Davies; Julius M Guccione; Thomas Franz
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.